✓ Independent editorial reviews of U.S. telehealth providers · Updated June 1, 2026 · Educational only — not medical advice
Journal · Telehealth analysis

American Telehealth Review Journal

Editorial analysis on telehealth legitimacy, pricing transparency, pharmacy oversight, and patient safety.

Published by Ranika Editorial Group LLCUpdated June 1, 2026
Journal · Evidence review · June 1, 2026

SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head (2025 Evidence)

What the 2025 SURMOUNT-5 head-to-head trial showed about tirzepatide versus semaglutide for weight loss.

Journal · Evidence review · June 1, 2026

What the STEP Trials Show About Semaglutide for Weight Loss

A plain-language summary of the STEP trial evidence for semaglutide weight loss.

Journal · Evidence review · June 1, 2026

SELECT Trial: Semaglutide and Cardiovascular Risk, Explained

What the SELECT trial showed about semaglutide and heart outcomes.

Journal · Evidence review · June 1, 2026

Oral GLP-1s in 2025: Orforglipron and Oral Semaglutide Evidence

What 2025 trials showed about oral GLP-1 options.

Journal · Evidence review · June 1, 2026

How Much Weight Loss Can You Expect on GLP-1s? Trial Data vs Real World

Trial averages vs real-world GLP-1 weight loss and why the gap exists.

Journal · Evidence review · June 1, 2026

Muscle Loss on GLP-1s: What the Research Shows and How to Protect Lean Mass

What research shows about lean-mass loss on GLP-1s and how to protect muscle.

Journal · Evidence review · June 1, 2026

Weight Regain After Stopping GLP-1s: What the Evidence Shows

What STEP 4 and related evidence show about regain after stopping GLP-1s.

Journal · Evidence review · June 1, 2026

GLP-1 Side Effects: What the Evidence Says and How They're Managed

Common GLP-1 side effects in trials and how titration and oversight reduce them.

Journal · Evidence review · June 1, 2026

FLOW Trial: Semaglutide and Kidney Outcomes, Explained

What the FLOW trial showed about semaglutide and kidney disease progression.

Journal · Evidence review · June 1, 2026

Choosing an Evidence-Based GLP-1 Telehealth Provider

How to match strong clinical evidence to a telehealth provider's actual practice.

Journal · June 1, 2026

How to Tell If an Online GLP-1 Provider Is Legit

Practical signs an online GLP-1 telehealth provider is legitimate: state-licensed clinicians, real medical review, disclosed pharmacy, transparent pricing, and accurate compounding language.

Journal · June 1, 2026

Why Telehealth Pricing Transparency Matters for Weight-Loss Patients

Why pricing transparency matters in weight-loss telehealth: teaser rates, dose-based pricing, hidden fees, and how to find the true monthly cost.

Journal · June 1, 2026

The Difference Between a Telehealth Platform, Medical Group, and Pharmacy

Telehealth platform vs medical group vs pharmacy: who does what in an online GLP-1 program, and why the distinction matters for oversight and accountability.

Journal · June 1, 2026

What Patients Should Ask Before Starting Online Weight-Loss Medication

The key questions to ask before starting online weight-loss medication: eligibility, side effects, pricing, pharmacy, support, and cancellation terms.

Journal · June 1, 2026

Compounded GLP-1 Marketing Claims: What Patients Should Watch For

Misleading compounded GLP-1 marketing claims to watch for — “generic Ozempic,” “FDA-approved compounded,” guaranteed results — and what the accurate language is.